Edition:
United States

Endocyte Inc (ECYT.OQ)

ECYT.OQ on NASDAQ Stock Exchange Global Select Market

23.84USD
14 Dec 2018
Change (% chg)

$-0.02 (-0.08%)
Prev Close
$23.86
Open
$23.88
Day's High
$23.88
Day's Low
$23.84
Volume
300,882
Avg. Vol
611,989
52-wk High
$23.94
52-wk Low
$2.86

Chart for

About

Endocyte Inc. (Endocyte) is a biopharmaceutical company. The Company is engaged in developing therapies for the treatment of cancer and inflammatory diseases. The Company uses its technology to create small molecule drug conjugates (SMDCs) and companion imaging diagnostics. The Company's pipeline includes Folate-Tubulysin... (more)

Overall

Beta: 0.04
Market Cap(Mil.): $1,936.47
Shares Outstanding(Mil.): 82.09
Dividend: --
Yield (%): --

Financials

  ECYT.OQ Industry Sector
P/E (TTM): -- 95.96 30.88
EPS (TTM): -0.68 -- --
ROI: -18.37 0.60 13.80
ROE: -18.42 -2.18 15.29

BRIEF-Endocyte - On Nov 30, Waiting Period With Respect To Filing Under Hart-Scott-Rodino Act Expired In Connection With Proposed Merger With Novartis AG

* ENDOCYTE SAYS ON NOV 30, 2018, WAITING PERIOD WITH RESPECT TO FILING UNDER HART-SCOTT-RODINO ACT EXPIRED IN CONNECTION WITH PROPOSED MERGER WITH NOVARTIS AG Source text: [https://bit.ly/2SogDFh] Further company coverage:

Dec 03 2018

Deals of the day-Mergers and acquisitions

Oct 18 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Thursday:

Oct 18 2018

Novartis pushes deeper into nuclear medicine with $2.1 billion deal

ZURICH Novartis is paying $2.1 billion for nuclear medicine specialist Endocyte in Chief Executive Vas Narasimhan's latest deal to reshape the Swiss drugs group from a pillmaker to a producer of sophisticated therapies.

Oct 18 2018

UPDATE 2-Novartis pushes deeper into nuclear medicine with $2.1 bln deal

* Analysts say Q3 results take back seat to deal (Adds comments from CEO, shares, details throughout)

Oct 18 2018

Novartis to buy cancer drugmaker Endocyte for $2.1 billion in cash

Novartis AG will acquire U.S.-based cancer drugmaker Endocyte Inc for $2.1 billion in cash as the Swiss drugmaker expands its radiopharmaceuticals business, the companies said on Thursday.

Oct 18 2018

UPDATE 1-Novartis to buy cancer drugmaker Endocyte for $2.1 bln in cash

Oct 18 Novartis AG will acquire U.S.-based cancer drugmaker Endocyte Inc for $2.1 billion in cash as the Swiss drugmaker expands its radiopharmaceuticals business, the companies said on Thursday.

Oct 18 2018

BRIEF-Novartis To Buy Endocyte In $2.1 Bln Deal

* NOVARTIS ANNOUNCES PLANNED ACQUISITION OF ENDOCYTE TO EXPAND EXPERTISE IN RADIOPHARMACEUTICALS AND BUILD ON COMMITMENT TO TRANSFORMATIONAL THERAPEUTIC PLATFORMS

Oct 18 2018

Novartis to buy Endocyte for $2.1 billion in cash

Oct 18 Biopharmaceutical company Endocyte Inc said on Thursday that Novartis AG will acquire Endocyte in an all-cash deal for $24 per share, or a total equity value of about $2.1 billion.

Oct 18 2018

BRIEF-Endocyte Enters Into Agreement to be Acquired by Novartis AG for $2.1 Billion

* ENDOCYTE ENTERS INTO AGREEMENT TO BE ACQUIRED BY NOVARTIS AG FOR $2.1 BILLION

Oct 18 2018

Earnings vs. Estimates